BMS-Capital

What BMS-Capital does

BMS-Capital Future Investments is a privately held Swiss investment firm headquartered in Zürich with a secondary office in Geneva. The company finances and develops biotechnology and healthcare companies while also operating a life science real estate investment product for investors. Its core offering combines funded research services, state-of-the-art laboratory facilities, and certified laboratory space leased to life science start-ups and researchers, paired with investment vehicles marketed to investors seeking security and yields above traditional real estate. Supporting modules include clinical and university cooperations, international ethics committee access, and a co-innovation platform intended to connect investors with scientists in active technology development.

The business model spans two customer segments. The primary segment consists of scientists and start-ups in life sciences who receive funded research, first-class laboratories, discretion, and access to clinical and university cooperations and ethics committees. The secondary segment comprises life science investors who gain exposure to specialized real estate with long-term anchor leases, certified laboratory space, and industry cooperations. The firm claims that life science real estate is less vulnerable to economic downturns than traditional real estate and generates steady cash flow through anchor leases, positioning returns above conventional real estate benchmarks.

The firm operates as a direct, network-driven investment platform rather than through intermediaries or digital channels. It collaborates with government organizations in Switzerland and EU member countries and maintains an international network of partners for deal sourcing and portfolio support. The team comprises an Investment Executive (Yasmin Kraupnam, Geneva) and a Research Executive (Björn Adrian Hoppe, Zürich), drawing on backgrounds in software engineering and healthcare research ecosystems. No funding rounds, revenue figures, AUM, ownership structure, or portfolio composition are disclosed in available source material, representing material information gaps for any prospective investor.

Name

BMS-Capital

Legal name

BMS-Capital Future Investments

Website

https://bms-capital.ch

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

BMS-Capital is a privately held Swiss investment firm that finances and develops biotechnology and healthcare companies while offering life science real estate investments with certified laboratory space and long-term anchor leases, serving scientists, life science start-ups, and investors.

Ownership category

akta.pro rank

Product category

Life Science Investment Services

NAICS

Funds, Trusts, and Other Financial Vehicles (525), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Other Financial Vehicles (52599)

SIC

Real Estate Dealers (For Their Own Account) (6532), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

akta.pro secondary industry

Corporate Strategic Real Assets & Infrastructure Venture Investing (FSANAHAN)

Keywords

• Life science investment
• Biotechnology financing
• Research laboratory services
• Healthcare venture capital
• Life science real estate

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Marketing or Sales

Core offering

BMS-Capital finances and develops groundbreaking biotechnology and healthcare companies while providing investors exposure to life science real estate through long-term anchor leases. The firm delivers funded research to scientists and start-ups, certified first-class research laboratories, clinical and university cooperation access, and a co-innovation platform that connects capital with research. Its investment strategy targets high-yield returns tied to specialized laboratory real estate with security characteristics that outpace traditional real estate.

Product overview

BMS-Capital is a life science investment company operating as a unified platform that connects researchers, scientists, and start-ups with investors. The core offering consists of Funded Research services that provide capital to biotechnology and healthcare innovators, paired with First Class Research Laboratories offering certified facilities. For investors, the Life Science Real Estate Investments product delivers security and high yields through specialized laboratory spaces with long-term anchor leases. Supporting these core offerings are Clinical and University Cooperations that facilitate research partnerships, and a Co-Innovation Platform enabling collaborative participation in the sector's advancement. The platform leverages strategic partnerships with government organizations in Switzerland and EU member countries, and maintains an international network across medicine, pharmacy, and biotechnology.

Differentiator

Problem solved

Functional benefit

Products and services

• Funded Research Capital financing service that connects investors with scientists and start-ups in the life science sector to enable groundbreaking biotechnology and healthcare innovation. Targeted at researchers and founders operating in the life sciences.
• First Class Research Laboratories Provision of certified, state-of-the-art laboratory facilities to researchers and start-ups in the life science sector, supplying the physical infrastructure needed for advanced biotechnology and healthcare research.
• Life Science Real Estate Investments Investment product offering investors exposure to life science real estate assets with security and yields targeted to outpace traditional real estate, structured through long-term anchor leases in certified laboratory properties. Designed for investors seeking alternatives to traditional real estate investment.

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Index Ventures: Major European-headquartered venture firm with a dedicated life sciences practice investing across Europe and the US; comparable as a broader European VC competing for similar early-stage biotech opportunities.
• Alexandria Real Estate Equities: Largest US-focused REIT specializing in life science laboratory and innovation cluster real estate; comparable as the established incumbent defining the life science real estate category BMS-Capital operates in.
• Kadans Science Partner: European specialist in life science real estate providing laboratory and incubator space across the continent; comparable for BMS-Capital's life science real estate and laboratory infrastructure product line.

Emerging players

• Breakthrough Properties: Joint venture between TPG Real Estate and Bellco Capital focused on developing and operating life science research buildings globally; comparable as a more recent entrant into life science real estate with similar tenant-scientist-investor ecosystem play.

Direct peers

• Roche Venture Fund: Swiss-based life sciences venture investor backing innovative healthcare and biotech companies; shares the Swiss anchor and the focus on financing groundbreaking biotechnology that defines BMS-Capital's mission.
• BioMedPartners: Swiss-based venture capital firm investing in early- to mid-stage biotech and medtech companies; closely comparable Swiss biotech VC with a similar focus on supporting innovative life sciences founders.
• HBM Healthcare Investments: Zurich-listed investment company focused on private and public healthcare/biotech companies; highly comparable as a Swiss-domiciled healthcare growth investment vehicle with a similar investor base.
• EQT Life Sciences (formerly LSP): European healthcare and life sciences growth equity investor with offices across Europe; comparable as a pan-European life sciences growth investor targeting similar biotech opportunities.
• Novartis Venture Fund: Swiss-based corporate venture arm investing in early-stage biotechnology and life sciences companies, directly comparable to BMS-Capital's core biotech financing activity and Swiss geographic base.
• Pureos Bioventures: Swiss venture capital firm investing exclusively in private biotech companies developing innovative therapeutics; directly comparable early-stage Swiss biotech investor.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/bms-capital

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BMS-Capital